EX-23.1 4 tm2129373d2_ex23-1.htm EXHIBIT 23.1

 

Exhibit 23.1 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our report dated March 11, 2021, with respect to the consolidated financial statements of Nabriva Therapeutics plc incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.

 

/s/ KPMG LLP

 

Philadelphia, Pennsylvania

October 8, 2021